Impact of Tuberculosis Co-infection on Cytokine Expression in HIV-Infected Individuals

Authors: M. Nosik, I. Rymanova, N. Adamovich, S. Sevostyanihin, K. Ryzhov, Y. Kuimova, A. Kravtchenko, N. Sergeeva, A. Sobkin

Abstract:

HIV and Tuberculosis (TB) infections each speed the other's progress. HIV-infection increases the risk of TB disease. At the same time, TB infection is associated with clinical progression of HIV-infection. HIV+TB co-infected patients are also at higher risk of acquiring new opportunistic infections. An important feature of disease progression and clinical outcome is the innate and acquired immune responses. HIV and TB, however, have a spectrum of dysfunctions of the immune response. As cytokines play a crucial role in the immunopathology of both infections, it is important to study immune interactions in patients with dual infection HIV+TB. Plasma levels of proinflammatory cytokines IL-2, IFN-γ and immunoregulating cytokines IL-4, IL-10 were evaluated in 75 patients with dual infection HIV+TB, 58 patients with HIV monoinfection and 50 patients with TB monoinfection who were previously naïve for HAART. The decreased levels of IL-2, IFN-γ, IL-4 and IL-10 were observed in patients with dual infection HIV+TB in comparison with patients who had only HIV or TB which means the profound suppression of Th1 and Th2 cytokine secretion. Thus, those cytokines could possibly serve as immunological markers of progression of HIV-infection in patients with TB.

Keywords: HIV, Tuberculosis, TB, HIV associated with TB, Th1/ Th2 cytokine expression.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1123554

References:

[1] WHO. Global tuberculosis report, 2014.
[2] WHO. Tuberculosis. Fact sheet N°104. Updated October 2015.
[3] K. Naidoo et al., “HIV-associated Tuberculosis”. Clin Dev Immunol, 2011, p.1-8.
[4] E. Walters and et al., “Clinical presentation and outcome of tuberculosis in hguman immunodeficiency virus infected cgildren on anti-retroviral therapy”. BMC Pediatrics, 2008, vol.8: pp.
[5] H.J. Zar et al., “Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial”. British med J, 2007, vol.334 (7585): pp.136-139.
[6] Global report. “UNAIDS report on the global AIDS epidemic 2013”, UNAIDS, 2013.
[7] Newsletter No. 39. “HIV-infection”. Federal Research and Methodological Centre for Disease Prevention and Control of AIDS, Russian Federation, 2014.
[8] Tuberculosis in Russian Federation. Analytical review, 2013.
[9] WHO. Global tuberculosis control: a short update to the 2009 report, 2009.
[10] UNAIDS. Fact sheet: 2014 Global statistics, 2015.
[11] H. Getahun et al., “HIV infection-associated tuberculosis: the epidemiology and the response”. Clin Infect Dis, 2010, vol. 50 (Suppl 3): S201–S207.
[12] D. Maher et al., “Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies”. Trop Medicine and Intern Health, 2005, vol.10(8): pp734–742.
[13] E.L. Korenromp et al., “Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review”. Clin Infect Dis, 2003, vol.37(1): pp.101–112.
[14] Z. Toossi et al., “Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation”. J Acquir Immune Defic Syndr, 2001, Vol.14: pp.1-8.
[15] T. Hertoghe et al., “T cell activation, apoptosis and cytokine dysregulation in the (co) pathogenesis of HIV and pulmonary tuberculosis (TB)”. Clin Exp Immunol, 2000, vol.14: pp.350-357.
[16] D. Goletti et al., “Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation”. J Immunol, 1996, vol.14: pp.1271-1278.
[17] G. Poli, A.S. Fauci, “Cytokine modulation of HIV expression”. J Semin Immunol, 1993, vol.5(3): pp.165-167.
[18] S. Subramanyam et al., “HIV alters plasma and M. tuberculosis-induced cytokine production in patients with tuberculosis”. J Interferon Cytokine Res, 2004, vol.24: pp.101-106.
[19] J.L. Flynn et al., “An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection”. J Exp Med, 1993, vol.178, pp.2249-2254.
[20] N.W. Schluger, W.N. Rom, “The host immune response to tuberculosis”. Am J Respir Crit Care Med, 1998, vol.157: pp.679-691.
[21] A.M. Green, R. Difazio, J.L. Flynn, “INF -gamma from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection”. J Immunol, 2013, vol.190: pp.270-277.
[22] R.J. North, Y.J. Jung, “Immunity to tuberculosis”. Annu Rev Immunol, 2004, vol.22: pp.599-623.
[23] R. Van Crevel, T.H.M. Ottenhoff, J.W.M. van der Meer, “Innate immunity to Mycobacterium tuberculosis”. Clin Microbiol Rev, 2002, vol.15: pp.294-309.
[24] R. Benjamin et al., “Discordance in CD4+T-cell levels and viral loads with co-occurrence of elevated peripheral TNF-α and IL-4 in newly diagnosed HIV-TB co-infected cases”. 2013, PLoS ONE 8(8):e70250.
[25] A.M. Bal et al., “Dysregulation of proinflammatory and regulatory cytokines in HIV infected persons with active tuberculosis”. Cytokine, 2005, vol.30: pp.275-281.
[26] M. Zhang, “T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection”, J Clin Ivest, 1994, vol.94: p.2435-2442.
[27] A. Sodhi et al., “Clinical correlates of interferon γ production in patients with tuberculosis”. Clin Infect Dis, 1997, vol.25: pp.617-620.
[28] S.K. Agarwal et al., “Cytokine profile in human immunodeficiency virus positive patients with and without tuberculosis”. J Assoc Physicians India, 2001, vol.49: pp.799-802
[29] Y.V. Cavalcanti et al., “Evaluation of memory immune response to mycobacterium extract”. J Clin Lab Anal, 2009, vol.23(1): pp.57-62.
[30] L. Lajoie et al., “Differences in immunoregulatory cytokine expression patterns in the systemic and genital tract compartmnets of HIV-1-infected commercial sex workers in Benin”. J Mucosal Immunol, 2008, vol.1(4): pp.309-316.
[31] Z. Toosi et al., “Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients”. Clin Exp Immunol, 2001, vol.14: pp.233-238.
[32] R. Sutherland et al., “Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cell during chronic HIV-1 infection despite long-term HAART”. AIDS, 2006, vol.14: pp.821-829.
[33] H. Mayanja-Kizza et al., “Macrophage-activating cytokines in human immunodeficiency virus type 1-infected and –uninfected patients with pulmonary tuberculosis”. J Infect Dis, 2001, vol.183(12): pp.1805-1809.
[34] S. Winkler et al., “Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa”. Microbes and Infection, 2005, vol. 7(9): pp.1161-1169.
[35] Myoung-Don Oh et al., “Cytokine responses induced by Mycobacterium tuberculosis in patients with HIV-1 infection and tuberculosis”. Int J Infect Dis, 2005, vol.9(2): pp.110-116.
[36] A. Salvaggio et al., “CD4 count in HIV infection is positively correlated to interferon-gamma and negatively correlated to interleukin-10 in vitro production”. AIDS, 1996, vol.10: pp.449-451.
[37] J. Wang et al., “Cytokine regulation of immunodeficiency virus type 1 entry and replication inn human monocytes/macrophages through modulation of CCR5 expression”. J Virol, 1998, vol.72(9): pp.7642-7647.
[38] A. Valentin et al. “Dual effect of interleukin- 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression”. Proc Natl Acad Sci USA, 1998, 95(15): pp.8886–8891.
[39] E.E. Nakayama EE et al., “Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype”. J Virol, 2000, vol.74(12): pp.5452–5459.
[40] E.E. Nakayama EE et al. “Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load”. J Infect Dis, 2002, vol.85(8): pp.1183–1186.
[41] G.A.W. Rook et al., “IL-4 in tuberculosis: implications for vaccine design”. TRENDS Immunol, 2004, vol.25: pp.483-488.
[42] G.T. Seah, G.A.W. Rook, “High levels of mRNA IL=4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested reverse transcriptase polymerase chain reaction; correlations with serum IgE levels”. Scand J Infect Dis, 2001, vol.33: pp.106-109.
[43] D. Dlugovizky et al., “In vitro synthesis of interferon-gamma, inerleukin-4, transforming growth factor-beta and interleukin-1 by peripheral blood mononuclear cells from tuberculosis patients: relationship with the severity of pulmonary involvement”. Scand J Immunol, 199, vol.49: pp.210-217.
[44] S. Sindhu et al., “Relationship of in vivo and ex vivo levels of Th1 and Th2 cytokines with viremia in HAART patients with and without opportunistic infections”. J Med Virol, 2006, vol.78: pp.431-439.
[45] J. Lama, V. Planelles, “Host factors influencing susceptibility to HIV infection and AIDS progression”. Retrovirol, 2007, vol.4(52): pp.52-77.
[46] D. Weissman D, G. Poli, A.S. Fauci, “Interleukin- 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor alpha and interleukin- 6 induction of virus”. AIDS Res Hum Retroviruses, 1994, vol.10: pp.1199-1206.
[47] J.F. Arias et al., “High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses”. Retrovirology, 2010, vol.7: pp.1-15.
[48] H.D. Shin et al., “Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL-10”. Proc Natl Acad Sci USA, 2000, vol.97(26): pp.14467–14472.
[49] C.A. Bento et al., “IL-10-secreting T cells from HIV-infected pregnant women downregulate HIV-1 replication: effect enhanced by antiretroviral treatment”. AIDS, 2009, vol.23: pp.9-18.
[50] R.M. Andrade et al., “Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production”. AIDS, 2007, vol.21: pp.1763-1770.
[51] Y.V.N. Cavalcanti et al., “Role of TNF-alpha, IFN-gamma and IL-10 in the development of pulmonary tuberculosis”. Pulmon Med, 2012, pp.1-10.